ID   TOR1A_HUMAN             Reviewed;         332 AA.
AC   O14656; B2RB58; Q53Y64; Q96CA0;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   28-JAN-2026, entry version 219.
DE   RecName: Full=Torsin-1A;
DE   AltName: Full=Dystonia 1 protein;
DE   AltName: Full=Torsin ATPase-1A;
DE            EC=3.6.4.-;
DE   AltName: Full=Torsin family 1 member A;
DE   Flags: Precursor;
GN   Name=TOR1A; Synonyms=DQ2, DYT1, TA, TORA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT DYT1 GLU-303 DEL, AND
RP   VARIANT HIS-264.
RC   TISSUE=Brain cortex, Hippocampus, and Substantia nigra;
RX   PubMed=9288096; DOI=10.1038/ng0997-40;
RA   Ozelius L.J., Hewett J.W., Page C.E., Bressman S.B., Kramer P.L.,
RA   Shalish C., de Leon D., Brin M.F., Raymond D., Corey D.P., Fahn S.,
RA   Risch N.J., Buckler A.J., Gusella J.F., Breakefield X.O.;
RT   "The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding
RT   protein.";
RL   Nat. Genet. 17:40-48(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION AT ASN-143 AND ASN-158, AND MUTAGENESIS
RP   OF ASN-143 AND ASN-158.
RX   PubMed=10871631; DOI=10.1074/jbc.m910025199;
RA   Kustedjo K., Bracey M.H., Cravatt B.F.;
RT   "Torsin A and its torsion dystonia-associated mutant forms are lumenal
RT   glycoproteins that exhibit distinct subcellular localizations.";
RL   J. Biol. Chem. 275:27933-27939(2000).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=10640617; DOI=10.1016/s0006-8993(99)02232-5;
RA   Shashidharan P., Kramer B.C., Walker R.H., Olanow C.W., Brin M.F.;
RT   "Immunohistochemical localization and distribution of torsinA in normal
RT   human and rat brain.";
RL   Brain Res. 853:197-206(2000).
RN   [8]
RP   INTERACTION WITH TOR1B, TISSUE SPECIFICITY, GLYCOSYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15147511; DOI=10.1111/j.1471-4159.2004.02404.x;
RA   Hewett J.W., Kamm C., Boston H., Beauchamp R., Naismith T., Ozelius L.,
RA   Hanson P.I., Breakefield X.O., Ramesh V.;
RT   "TorsinB--perinuclear location and association with torsinA.";
RL   J. Neurochem. 89:1186-1194(2004).
RN   [9]
RP   INTERACTION WITH KLC1, TISSUE SPECIFICITY, CHARACTERIZATION OF VARIANT DYT1
RP   GLU-303 DEL, AND SUBCELLULAR LOCATION.
RX   PubMed=14970196; DOI=10.1074/jbc.m401332200;
RA   Kamm C., Boston H., Hewett J., Wilbur J., Corey D.P., Hanson P.I.,
RA   Ramesh V., Breakefield X.O.;
RT   "The early onset dystonia protein torsinA interacts with kinesin light
RT   chain 1.";
RL   J. Biol. Chem. 279:19882-19892(2004).
RN   [10]
RP   FUNCTION IN CELLULAR TRAFFICKING, SUBUNIT, INTERACTION WITH SLC6A3,
RP   CHARACTERIZATION OF VARIANT DYT1 GLU-303 DEL, AND MUTAGENESIS OF LYS-108.
RX   PubMed=15505207; DOI=10.1073/pnas.0308088101;
RA   Torres G.E., Sweeney A.L., Beaulieu J.M., Shashidharan P., Caron M.G.;
RT   "Effect of torsinA on membrane proteins reveals a loss of function and a
RT   dominant-negative phenotype of the dystonia-associated DeltaE-torsinA
RT   mutant.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15650-15655(2004).
RN   [11]
RP   INTERACTION WITH TOR1AIP1 AND TOR1AIP2.
RX   PubMed=15767459; DOI=10.1083/jcb.200411026;
RA   Goodchild R.E., Dauer W.T.;
RT   "The AAA+ protein torsinA interacts with a conserved domain present in LAP1
RT   and a novel ER protein.";
RL   J. Cell Biol. 168:855-862(2005).
RN   [12]
RP   FUNCTION IN CYTOSKELETON ORGANIZATION, CHARACTERIZATION OF VARIANT DYT1
RP   GLU-303 DEL, SUBCELLULAR LOCATION, AND INTERACTION WITH VIM.
RX   PubMed=16361107; DOI=10.1016/j.nbd.2005.10.012;
RA   Hewett J.W., Zeng J., Niland B.P., Bragg D.C., Breakefield X.O.;
RT   "Dystonia-causing mutant torsinA inhibits cell adhesion and neurite
RT   extension through interference with cytoskeletal dynamics.";
RL   Neurobiol. Dis. 22:98-111(2006).
RN   [13]
RP   SUBCELLULAR LOCATION, SIGNAL SEQUENCE CLEAVAGE SITE, GLYCOSYLATION, AND
RP   MUTAGENESIS OF VAL-18; ALA-20 AND VAL-33.
RX   PubMed=17037984; DOI=10.1042/bj20061313;
RA   Callan A.C., Bunning S., Jones O.T., High S., Swanton E.;
RT   "Biosynthesis of the dystonia-associated AAA+ ATPase torsinA at the
RT   endoplasmic reticulum.";
RL   Biochem. J. 401:607-612(2007).
RN   [14]
RP   FUNCTION IN PROTEIN PROCESSING, AND CHARACTERIZATION OF VARIANT DYT1
RP   GLU-303 DEL.
RX   PubMed=17428918; DOI=10.1073/pnas.0701185104;
RA   Hewett J.W., Tannous B., Niland B.P., Nery F.C., Zeng J., Li Y.,
RA   Breakefield X.O.;
RT   "Mutant torsinA interferes with protein processing through the secretory
RT   pathway in DYT1 dystonia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7271-7276(2007).
RN   [15]
RP   FUNCTION IN VESICLE RECYCLING, INTERACTION WITH SNAPIN, AND
RP   CHARACTERIZATION OF VARIANT DYT1 GLU-303 DEL.
RX   PubMed=18167355; DOI=10.1074/jbc.m704097200;
RA   Granata A., Watson R., Collinson L.M., Schiavo G., Warner T.T.;
RT   "The dystonia-associated protein torsinA modulates synaptic vesicle
RT   recycling.";
RL   J. Biol. Chem. 283:7568-7579(2008).
RN   [16]
RP   FUNCTION IN NUCLEAR POLARITY, INTERACTION WITH PLEC; SYNE3 AND VIM, AND
RP   CHARACTERIZATION OF VARIANT DYT1 GLU-303 DEL.
RX   PubMed=18827015; DOI=10.1242/jcs.029454;
RA   Nery F.C., Zeng J., Niland B.P., Hewett J., Farley J., Irimia D., Li Y.,
RA   Wiche G., Sonnenberg A., Breakefield X.O.;
RT   "TorsinA binds the KASH domain of nesprins and participates in linkage
RT   between nuclear envelope and cytoskeleton.";
RL   J. Cell Sci. 121:3476-3486(2008).
RN   [17]
RP   INTERACTION WITH KLHL14, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-108
RP   AND GLU-171.
RX   PubMed=19535332; DOI=10.1074/jbc.m109.004838;
RA   Giles L.M., Li L., Chin L.S.;
RT   "Printor, a novel torsinA-interacting protein implicated in dystonia
RT   pathogenesis.";
RL   J. Biol. Chem. 284:21765-21775(2009).
RN   [18]
RP   FUNCTION, HEXAMERIZATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-108
RP   AND GLU-171.
RX   PubMed=19339278; DOI=10.1091/mbc.e09-01-0094;
RA   Vander Heyden A.B., Naismith T.V., Snapp E.L., Hodzic D., Hanson P.I.;
RT   "LULL1 retargets TorsinA to the nuclear envelope revealing an activity that
RT   is impaired by the DYT1 dystonia mutation.";
RL   Mol. Biol. Cell 20:2661-2672(2009).
RN   [19]
RP   FUNCTION AS CHAPERONE, AND CHARACTERIZATION OF VARIANT DYT1 GLU-303 DEL.
RX   PubMed=20169475; DOI=10.1007/s12192-010-0173-2;
RA   Burdette A.J., Churchill P.F., Caldwell G.A., Caldwell K.A.;
RT   "The early-onset torsion dystonia-associated protein, torsinA, displays
RT   molecular chaperone activity in vitro.";
RL   Cell Stress Chaperones 15:605-617(2010).
RN   [20]
RP   SUBUNIT, AND MUTAGENESIS OF GLU-171.
RX   PubMed=20015956; DOI=10.1093/hmg/ddp557;
RA   Jungwirth M., Dear M.L., Brown P., Holbrook K., Goodchild R.;
RT   "Relative tissue expression of homologous torsinB correlates with the
RT   neuronal specific importance of DYT1 dystonia-associated torsinA.";
RL   Hum. Mol. Genet. 19:888-900(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   INTERACTION WITH CSN4; SNAPIN AND STON2, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANT DYT1 GLU-303 DEL.
RX   PubMed=21102408; DOI=10.1038/emboj.2010.285;
RA   Granata A., Koo S.J., Haucke V., Schiavo G., Warner T.T.;
RT   "CSN complex controls the stability of selected synaptic proteins via a
RT   torsinA-dependent process.";
RL   EMBO J. 30:181-193(2011).
RN   [23]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TOR1AIP1 AND TOR1AIP2,
RP   CHARACTERIZATION OF VARIANT GLU-303 DEL, AND MUTAGENESIS OF GLU-171.
RX   PubMed=23569223; DOI=10.1073/pnas.1300676110;
RA   Zhao C., Brown R.S., Chase A.R., Eisele M.R., Schlieker C.;
RT   "Regulation of Torsin ATPases by LAP1 and LULL1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1545-1554(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [25]
RP   INVOLVEMENT IN AMC5, VARIANTS AMC5 GLU-303 DEL AND SER-318,
RP   CHARACTERIZATION OF VARIANT AMC5 SER-318, AND SUBCELLULAR LOCATION.
RX   PubMed=29053766; DOI=10.1093/brain/awx230;
RA   Kariminejad A., Dahl-Halvarsson M., Ravenscroft G., Afroozan F.,
RA   Keshavarz E., Goullee H., Davis M.R., Faraji Zonooz M., Najmabadi H.,
RA   Laing N.G., Tajsharghi H.;
RT   "TOR1A variants cause a severe arthrogryposis with developmental delay,
RT   strabismus and tremor.";
RL   Brain 140:2851-2859(2017).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 51-332 IN COMPLEX WITH TOR1AIP2,
RP   CHARACTERIZATION OF VARIANT DYT1 GLU-303 DEL, AND MUTAGENESIS OF GLU-171.
RX   PubMed=27490483; DOI=10.7554/elife.17983;
RA   Demircioglu F.E., Sosa B.A., Ingram J., Ploegh H.L., Schwartz T.U.;
RT   "Structures of TorsinA and its disease-mutant complexed with an activator
RT   reveal the molecular basis for primary dystonia.";
RL   Elife 5:0-0(2016).
RN   [27]
RP   VARIANT 323-PHE--TYR-328 DEL.
RX   PubMed=11523564; DOI=10.1007/s100480100111;
RA   Leung J.C., Klein C., Friedman J., Vieregge P., Jacobs H., Doheny D.,
RA   Kamm C., DeLeon D., Pramstaller P.P., Penney J.B., Eisengart M.,
RA   Jankovic J., Gasser T., Bressman S.B., Corey D.P., Kramer P., Brin M.F.,
RA   Ozelius L.J., Breakefield X.O.;
RT   "Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia
RT   and polymorphisms in dystonia and early onset parkinsonism.";
RL   Neurogenetics 3:133-143(2001).
RN   [28]
RP   VARIANT DYT1 GLN-288, AND CHARACTERIZATION OF VARIANTS DYT1 GLN-288 AND
RP   GLU-303 DEL.
RX   PubMed=18477710; DOI=10.1136/jnnp.2008.148270;
RA   Zirn B., Grundmann K., Huppke P., Puthenparampil J., Wolburg H., Riess O.,
RA   Muller U.;
RT   "Novel TOR1A mutation p.Arg288Gln in early-onset dystonia (DYT1).";
RL   J. Neurol. Neurosurg. Psych. 79:1327-1330(2008).
RN   [29]
RP   VARIANT DYT1 ILE-205, AND CHARACTERIZATION OF VARIANTS DYT1 ILE-205 AND
RP   GLU-303 DEL.
RX   PubMed=19955557; DOI=10.1136/jmg.2009.072082;
RA   Calakos N., Patel V.D., Gottron M., Wang G., Tran-Viet K.N., Brewington D.,
RA   Beyer J.L., Steffens D.C., Krishnan R.R., Zuechner S.;
RT   "Functional evidence implicating a novel TOR1A mutation in idiopathic,
RT   late-onset focal dystonia.";
RL   J. Med. Genet. 47:646-650(2010).
RN   [30]
RP   CHARACTERIZATION OF VARIANTS DYT1 ILE-205; GLN-288 AND GLU-303 DEL,
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=24930953; DOI=10.1002/humu.22602;
RA   Hettich J., Ryan S.D., de Souza O.N., Saraiva Macedo Timmers L.F., Tsai S.,
RA   Atai N.A., da Hora C.C., Zhang X., Kothary R., Snapp E., Ericsson M.,
RA   Grundmann K., Breakefield X.O., Nery F.C.;
RT   "Biochemical and cellular analysis of human variants of the DYT1 dystonia
RT   protein, TorsinA/TOR1A.";
RL   Hum. Mutat. 35:1101-1113(2014).
RN   [31]
RP   VARIANT HIS-216.
RX   PubMed=26940431; DOI=10.1111/ane.12579;
RA   Piovesana L.G., Torres F.R., Azevedo P.C., Amaral T.P., Lopes-Cendes I.,
RA   D'Abreu A.;
RT   "New THAP1 mutation and role of putative modifier in TOR1A.";
RL   Acta Neurol. Scand. 135:183-188(2017).
RN   [32]
RP   VARIANT AMC5 GLU-303 DEL.
RX   PubMed=28516161; DOI=10.1212/nxg.0000000000000154;
RA   Reichert S.C., Gonzalez-Alegre P., Scharer G.H.;
RT   "Biallelic TOR1A variants in an infant with severe arthrogryposis.";
RL   Neurol. Genet. 3:e154-e154(2017).
RN   [33]
RP   VARIANT AMC5 288-ARG--ASP-332 DEL.
RX   PubMed=30244176; DOI=10.1016/j.ejmg.2018.09.011;
RA   Isik E., Aykut A., Atik T., Cogulu O., Ozkinay F.;
RT   "Biallelic TOR1A mutations cause severe arthrogryposis: A case requiring
RT   reverse phenotyping.";
RL   Eur. J. Med. Genet. 62:103544-103544(2019).
CC   -!- FUNCTION: Protein with chaperone functions important for the control of
CC       protein folding, processing, stability and localization as well as for
CC       the reduction of misfolded protein aggregates. Involved in the
CC       regulation of synaptic vesicle recycling, controls STON2 protein
CC       stability in collaboration with the COP9 signalosome complex (CSN). In
CC       the nucleus, may link the cytoskeleton with the nuclear envelope, this
CC       mechanism seems to be crucial for the control of nuclear polarity, cell
CC       movement and, specifically in neurons, nuclear envelope integrity.
CC       Participates in the cellular trafficking and may regulate the
CC       subcellular location of multipass membrane proteins such as the
CC       dopamine transporter SLC6A3, leading to the modulation of dopamine
CC       neurotransmission. In the endoplasmic reticulum, plays a role in the
CC       quality control of protein folding by increasing clearance of misfolded
CC       proteins such as SGCE variants or holding them in an intermediate state
CC       for proper refolding. May have a redundant function with TOR1B in non-
CC       neural tissues. {ECO:0000269|PubMed:15505207,
CC       ECO:0000269|PubMed:16361107, ECO:0000269|PubMed:17428918,
CC       ECO:0000269|PubMed:18167355, ECO:0000269|PubMed:18827015,
CC       ECO:0000269|PubMed:19339278, ECO:0000269|PubMed:20169475,
CC       ECO:0000269|PubMed:23569223, ECO:0000269|PubMed:24930953}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:23569223};
CC   -!- SUBUNIT: Homohexamer. Interacts with TOR1B; the interaction may be
CC       specific of neural tissues. Interacts (ATP-bound) with TOR1AIP1 and
CC       TOR1AIP2; the interactions induce ATPase activity. Interacts with
CC       KLHL14; preferentially when ATP-free. Interacts with KLC1 (via TPR
CC       repeats); the interaction associates TOR1A with the kinesin oligomeric
CC       complex. Interacts with COPS4; the interaction associates TOR1A with
CC       the CSN complex. Interacts with SNAPIN; the interaction is direct and
CC       associates SNAPIN with the CSN complex. Interacts with STON2. Interacts
CC       (ATP-bound) with SYNE3 (via KASH domain); the interaction is required
CC       for SYNE3 nuclear envelope localization. Interacts with VIM; the
CC       interaction associates TOR1A with the cytoskeleton. Interacts with
CC       PLEC. Interacts (ATP-bound) with SLC6A3; regulates SLC6A3 transport to
CC       the plasma membrane. {ECO:0000269|PubMed:14970196,
CC       ECO:0000269|PubMed:15147511, ECO:0000269|PubMed:15505207,
CC       ECO:0000269|PubMed:15767459, ECO:0000269|PubMed:16361107,
CC       ECO:0000269|PubMed:18167355, ECO:0000269|PubMed:18827015,
CC       ECO:0000269|PubMed:19535332, ECO:0000269|PubMed:20015956,
CC       ECO:0000269|PubMed:21102408, ECO:0000269|PubMed:23569223,
CC       ECO:0000269|PubMed:24930953, ECO:0000269|PubMed:27490483}.
CC   -!- INTERACTION:
CC       O14656; Q6PCB6: ABHD17C; NbExp=3; IntAct=EBI-524257, EBI-22011868;
CC       O14656; P05067: APP; NbExp=3; IntAct=EBI-524257, EBI-77613;
CC       O14656; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-524257, EBI-9089489;
CC       O14656; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-524257, EBI-350590;
CC       O14656; P22692: IGFBP4; NbExp=3; IntAct=EBI-524257, EBI-2831948;
CC       O14656; P60409: KRTAP10-7; NbExp=6; IntAct=EBI-524257, EBI-10172290;
CC       O14656; Q99750: MDFI; NbExp=3; IntAct=EBI-524257, EBI-724076;
CC       O14656; Q5JTV8: TOR1AIP1; NbExp=2; IntAct=EBI-524257, EBI-2559665;
CC       O14656; Q8NFQ8: TOR1AIP2; NbExp=6; IntAct=EBI-524257, EBI-524567;
CC       O14656-2; Q6PCB6: ABHD17C; NbExp=3; IntAct=EBI-25847109, EBI-22011868;
CC       O14656-2; P63010-2: AP2B1; NbExp=3; IntAct=EBI-25847109, EBI-11529439;
CC       O14656-2; P05067: APP; NbExp=3; IntAct=EBI-25847109, EBI-77613;
CC       O14656-2; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-25847109, EBI-718459;
CC       O14656-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-25847109, EBI-396137;
CC       O14656-2; Q53EZ4: CEP55; NbExp=3; IntAct=EBI-25847109, EBI-747776;
CC       O14656-2; Q96FZ7: CHMP6; NbExp=3; IntAct=EBI-25847109, EBI-1049648;
CC       O14656-2; Q92478: CLEC2B; NbExp=3; IntAct=EBI-25847109, EBI-13350535;
CC       O14656-2; P35222: CTNNB1; NbExp=3; IntAct=EBI-25847109, EBI-491549;
CC       O14656-2; Q9NR90-2: DAZ3; NbExp=3; IntAct=EBI-25847109, EBI-25830216;
CC       O14656-2; Q9UHI6: DDX20; NbExp=3; IntAct=EBI-25847109, EBI-347658;
CC       O14656-2; Q14154: DELE1; NbExp=3; IntAct=EBI-25847109, EBI-2805660;
CC       O14656-2; Q9H147: DNTTIP1; NbExp=3; IntAct=EBI-25847109, EBI-2795449;
CC       O14656-2; O75616: ERAL1; NbExp=3; IntAct=EBI-25847109, EBI-6393536;
CC       O14656-2; Q9UI08-2: EVL; NbExp=3; IntAct=EBI-25847109, EBI-6448852;
CC       O14656-2; Q6PIV2: FOXR1; NbExp=3; IntAct=EBI-25847109, EBI-10253815;
CC       O14656-2; Q9H4A5: GOLPH3L; NbExp=3; IntAct=EBI-25847109, EBI-4403434;
CC       O14656-2; P0C0S5: H2AZ1; NbExp=3; IntAct=EBI-25847109, EBI-1199859;
CC       O14656-2; Q6DN90-2: IQSEC1; NbExp=3; IntAct=EBI-25847109, EBI-21911304;
CC       O14656-2; Q8NA54: IQUB; NbExp=3; IntAct=EBI-25847109, EBI-10220600;
CC       O14656-2; Q92993: KAT5; NbExp=3; IntAct=EBI-25847109, EBI-399080;
CC       O14656-2; Q8IUB9: KRTAP19-1; NbExp=3; IntAct=EBI-25847109, EBI-12811111;
CC       O14656-2; A2RU56: LOC401296; NbExp=3; IntAct=EBI-25847109, EBI-9088215;
CC       O14656-2; Q8TDB4: MGARP; NbExp=3; IntAct=EBI-25847109, EBI-4397720;
CC       O14656-2; P41218: MNDA; NbExp=3; IntAct=EBI-25847109, EBI-2829677;
CC       O14656-2; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-25847109, EBI-995714;
CC       O14656-2; O43196-2: MSH5; NbExp=3; IntAct=EBI-25847109, EBI-25844576;
CC       O14656-2; O00746: NME4; NbExp=3; IntAct=EBI-25847109, EBI-744871;
CC       O14656-2; Q96CV9-2: OPTN; NbExp=3; IntAct=EBI-25847109, EBI-9091423;
CC       O14656-2; Q99497: PARK7; NbExp=3; IntAct=EBI-25847109, EBI-1164361;
CC       O14656-2; Q13113: PDZK1IP1; NbExp=3; IntAct=EBI-25847109, EBI-716063;
CC       O14656-2; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-25847109, EBI-9090282;
CC       O14656-2; P12273: PIP; NbExp=3; IntAct=EBI-25847109, EBI-1049746;
CC       O14656-2; O75626-3: PRDM1; NbExp=3; IntAct=EBI-25847109, EBI-25829882;
CC       O14656-2; P57729: RAB38; NbExp=3; IntAct=EBI-25847109, EBI-6552718;
CC       O14656-2; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-25847109, EBI-11984839;
CC       O14656-2; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-25847109, EBI-25837959;
CC       O14656-2; Q15019-3: SEPTIN2; NbExp=3; IntAct=EBI-25847109, EBI-11525407;
CC       O14656-2; Q9NQ40: SLC52A3; NbExp=3; IntAct=EBI-25847109, EBI-25845274;
CC       O14656-2; Q12824: SMARCB1; NbExp=3; IntAct=EBI-25847109, EBI-358419;
CC       O14656-2; Q05C28: SPACA3; NbExp=3; IntAct=EBI-25847109, EBI-25845337;
CC       O14656-2; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-25847109, EBI-10696971;
CC       O14656-2; O75558: STX11; NbExp=3; IntAct=EBI-25847109, EBI-714135;
CC       O14656-2; P21980-2: TGM2; NbExp=3; IntAct=EBI-25847109, EBI-25842075;
CC       O14656-2; Q9BUZ4: TRAF4; NbExp=3; IntAct=EBI-25847109, EBI-3650647;
CC       O14656-2; Q9NX07-2: TRNAU1AP; NbExp=3; IntAct=EBI-25847109, EBI-21894090;
CC       O14656-2; Q5JTY5: ZNG1C; NbExp=3; IntAct=EBI-25847109, EBI-723434;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum lumen
CC       {ECO:0000269|PubMed:29053766}. Nucleus membrane
CC       {ECO:0000269|PubMed:14970196, ECO:0000269|PubMed:29053766}; Peripheral
CC       membrane protein {ECO:0000305}. Cell projection, growth cone
CC       {ECO:0000250}. Cytoplasmic vesicle membrane {ECO:0000250}. Cytoplasmic
CC       vesicle, secretory vesicle {ECO:0000250}. Cytoplasmic vesicle,
CC       secretory vesicle, synaptic vesicle. Cytoplasm, cytoskeleton. Note=Upon
CC       oxidative stress, redistributes to protusions from the cell surface (By
CC       similarity). Peripherally associated with the inner face of the ER
CC       membrane, probably mediated by the interaction with TOR1AIP1. The
CC       association with nucleus membrane is mediated by the interaction with
CC       TOR1AIP2. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14656-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14656-2; Sequence=VSP_026605;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest levels in kidney and
CC       liver. In the brain, high levels found in the dopaminergic neurons of
CC       the substantia nigra pars compacta, as well as in the neocortex,
CC       hippocampus and cerebellum. Also highly expressed in the spinal cord.
CC       {ECO:0000269|PubMed:10640617, ECO:0000269|PubMed:14970196,
CC       ECO:0000269|PubMed:15147511}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10871631,
CC       ECO:0000269|PubMed:15147511, ECO:0000269|PubMed:17037984}.
CC   -!- DISEASE: Dystonia 1, torsion, autosomal dominant (DYT1) [MIM:128100]: A
CC       primary torsion dystonia, and the most common and severe form. Dystonia
CC       is defined by the presence of sustained involuntary muscle
CC       contractions, often leading to abnormal postures. Dystonia type 1 is
CC       characterized by involuntary, repetitive, sustained muscle contractions
CC       or postures involving one or more sites of the body, in the absence of
CC       other neurological symptoms. Typically, symptoms develop first in an
CC       arm or leg in middle to late childhood and progress in approximately
CC       30% of patients to other body regions (generalized dystonia) within
CC       about five years. 'Torsion' refers to the twisting nature of body
CC       movements observed in DYT1, often affecting the trunk. Distribution and
CC       severity of symptoms vary widely between affected individuals, ranging
CC       from mild focal dystonia to severe generalized dystonia, even within
CC       families. {ECO:0000269|PubMed:14970196, ECO:0000269|PubMed:15505207,
CC       ECO:0000269|PubMed:16361107, ECO:0000269|PubMed:17428918,
CC       ECO:0000269|PubMed:18167355, ECO:0000269|PubMed:18477710,
CC       ECO:0000269|PubMed:18827015, ECO:0000269|PubMed:19955557,
CC       ECO:0000269|PubMed:20169475, ECO:0000269|PubMed:21102408,
CC       ECO:0000269|PubMed:24930953, ECO:0000269|PubMed:27490483,
CC       ECO:0000269|PubMed:9288096}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Arthrogryposis multiplex congenita 5 (AMC5) [MIM:618947]: A
CC       form of arthrogryposis multiplex congenita, a developmental condition
CC       characterized by multiple joint contractures resulting from reduced or
CC       absent fetal movements. AMC5 is an autosomal recessive form
CC       characterized by severe congenital contractures, developmental delay,
CC       strabismus and tremor. {ECO:0000269|PubMed:28516161,
CC       ECO:0000269|PubMed:29053766, ECO:0000269|PubMed:30244176}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ClpA/ClpB family. Torsin subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF007871; AAC51732.1; -; mRNA.
DR   EMBL; AK314505; BAG37105.1; -; mRNA.
DR   EMBL; BT006931; AAP35577.1; -; mRNA.
DR   EMBL; AL158207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000674; AAH00674.1; -; mRNA.
DR   EMBL; BC014484; AAH14484.1; -; mRNA.
DR   CCDS; CCDS6930.1; -. [O14656-1]
DR   RefSeq; NP_000104.1; NM_000113.3. [O14656-1]
DR   PDB; 5J1S; X-ray; 1.40 A; A=51-332.
DR   PDB; 5J1T; X-ray; 1.40 A; A=51-332.
DR   PDB; 6OIF; EM; 4.40 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y=51-332.
DR   PDBsum; 5J1S; -.
DR   PDBsum; 5J1T; -.
DR   PDBsum; 6OIF; -.
DR   AlphaFoldDB; O14656; -.
DR   EMDB; EMD-20076; -.
DR   SMR; O14656; -.
DR   BioGRID; 108193; 112.
DR   CORUM; O14656; -.
DR   DIP; DIP-34411N; -.
DR   FunCoup; O14656; 2971.
DR   IntAct; O14656; 108.
DR   MINT; O14656; -.
DR   STRING; 9606.ENSP00000345719; -.
DR   GlyConnect; 1821; 2 N-Linked glycans (1 site).
DR   GlyCosmos; O14656; 2 sites, 2 glycans.
DR   GlyGen; O14656; 3 sites, 8 N-linked glycans (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; O14656; -.
DR   PhosphoSitePlus; O14656; -.
DR   BioMuta; TOR1A; -.
DR   jPOST; O14656; -.
DR   MassIVE; O14656; -.
DR   PaxDb; 9606-ENSP00000345719; -.
DR   PeptideAtlas; O14656; -.
DR   ProteomicsDB; 48152; -. [O14656-1]
DR   ProteomicsDB; 48153; -. [O14656-2]
DR   Pumba; O14656; -.
DR   ABCD; O14656; 1 sequenced antibody.
DR   Antibodypedia; 31437; 269 antibodies from 33 providers.
DR   DNASU; 1861; -.
DR   Ensembl; ENST00000351698.5; ENSP00000345719.4; ENSG00000136827.12. [O14656-1]
DR   GeneID; 1861; -.
DR   KEGG; hsa:1861; -.
DR   MANE-Select; ENST00000351698.5; ENSP00000345719.4; NM_000113.3; NP_000104.1.
DR   UCSC; uc004byl.4; human. [O14656-1]
DR   AGR; HGNC:3098; -.
DR   ClinPGx; PA27556; -.
DR   CTD; 1861; -.
DR   DisGeNET; 1861; -.
DR   GeneCards; TOR1A; -.
DR   GeneReviews; TOR1A; -.
DR   HGNC; HGNC:3098; TOR1A.
DR   HPA; ENSG00000136827; Low tissue specificity.
DR   MalaCards; TOR1A; -.
DR   MIM; 128100; phenotype.
DR   MIM; 605204; gene.
DR   MIM; 618947; phenotype.
DR   OpenTargets; ENSG00000136827; -.
DR   Orphanet; 256; Early-onset generalized limb-onset dystonia.
DR   Orphanet; 36899; Myoclonus-dystonia syndrome.
DR   VEuPathDB; HostDB:ENSG00000136827; -.
DR   eggNOG; KOG2170; Eukaryota.
DR   GeneTree; ENSGT00950000182888; -.
DR   HOGENOM; CLU_053537_0_0_1; -.
DR   InParanoid; O14656; -.
DR   OMA; YTKLDYY; -.
DR   OrthoDB; 19623at2759; -.
DR   PAN-GO; O14656; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; O14656; -.
DR   PathwayCommons; O14656; -.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   SignaLink; O14656; -.
DR   SIGNOR; O14656; -.
DR   Agora; ENSG00000136827; -.
DR   BioGRID-ORCS; 1861; 19 hits in 1163 CRISPR screens.
DR   ChiTaRS; TOR1A; human.
DR   GeneWiki; Torsin_A; -.
DR   GenomeRNAi; 1861; -.
DR   Pharos; O14656; Tbio.
DR   PRO; PR:O14656; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O14656; protein.
DR   Bgee; ENSG00000136827; Expressed in stromal cell of endometrium and 193 other cell types or tissues.
DR   ExpressionAtlas; O14656; baseline and differential.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:CACAO.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; ISS:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0030141; C:secretory granule; ISS:UniProtKB.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0140662; F:ATP-dependent protein folding chaperone; IDA:UniProtKB.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IMP:UniProtKB.
DR   GO; GO:0019894; F:kinesin binding; IPI:UniProtKB.
DR   GO; GO:0051787; F:misfolded protein binding; IEA:Ensembl.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; IMP:UniProtKB.
DR   GO; GO:0036503; P:ERAD pathway; ISS:UniProtKB.
DR   GO; GO:0045104; P:intermediate filament cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IMP:UniProtKB.
DR   GO; GO:0006998; P:nuclear envelope organization; ISS:UniProtKB.
DR   GO; GO:0071763; P:nuclear membrane organization; ISS:UniProtKB.
DR   GO; GO:1900244; P:positive regulation of synaptic vesicle endocytosis; IMP:UniProtKB.
DR   GO; GO:0000338; P:protein deneddylation; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IDA:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0051584; P:regulation of dopamine uptake involved in synaptic transmission; IDA:UniProtKB.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; IMP:GO_Central.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0048499; P:synaptic vesicle membrane organization; IMP:UniProtKB.
DR   GO; GO:0048489; P:synaptic vesicle transport; IMP:UniProtKB.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISS:UniProtKB.
DR   FunFam; 3.40.50.300:FF:000743; Torsin; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR049337; TOR1A_C.
DR   InterPro; IPR010448; Torsin.
DR   InterPro; IPR017378; Torsin_1/2.
DR   PANTHER; PTHR10760; TORSIN; 1.
DR   PANTHER; PTHR10760:SF15; TORSIN-1A; 1.
DR   Pfam; PF21376; TOR1A_C; 1.
DR   Pfam; PF06309; Torsin; 1.
DR   PIRSF; PIRSF038079; Torsin_2A; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Chaperone; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; Disease variant;
KW   Dystonia; Endoplasmic reticulum; Glycoprotein; Hydrolase; Membrane;
KW   Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome;
KW   Signal; Synapse.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000305|PubMed:17037984"
FT   CHAIN           21..332
FT                   /note="Torsin-1A"
FT                   /id="PRO_0000005506"
FT   REGION          91..251
FT                   /note="Interaction with SNAPIN"
FT   REGION          251..332
FT                   /note="Interaction with KLC1"
FT                   /evidence="ECO:0000269|PubMed:14970196"
FT   REGION          312..332
FT                   /note="Interaction with SYNE3"
FT                   /evidence="ECO:0000269|PubMed:18827015"
FT   BINDING         102..109
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   CARBOHYD        143
FT                   /note="N-linked (GlcNAc...) (high mannose) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10871631"
FT   CARBOHYD        158
FT                   /note="N-linked (GlcNAc...) (high mannose) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10871631"
FT   VAR_SEQ         149..332
FT                   /note="DQLQLWIRGNVSACARSIFIFDEMDKMHAGLIDAIKPFLDYYDLVDGVSYQK
FT                   AMFIFLSNAGAERITDVALDFWRSGKQREDIKLKDIEHALSVSVFNNKNSGFWHSSLID
FT                   RNLIDYFVPFLPLEYKHLKMCIRVEMQSRGYEIDEDIVSRVAEEMTFFPKEERVFSDKG
FT                   CKTVFTKLDYYYDD -> ARMEVWNPFLDVIGFGVSLLWDEIWEFYVEMSEPGKRFMSQ
FT                   FPLERCRS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_026605"
FT   VARIANT         205
FT                   /note="F -> I (in DYT1; increased identical protein
FT                   binding; decreased ATP-dependent chaperone mediated protein
FT                   folding; changed nuclear membrane organization; decreased
FT                   neuron projection development; dbSNP:rs267607134)"
FT                   /evidence="ECO:0000269|PubMed:19955557,
FT                   ECO:0000269|PubMed:24930953"
FT                   /id="VAR_070932"
FT   VARIANT         216
FT                   /note="D -> H (in dbSNP:rs1801968)"
FT                   /evidence="ECO:0000269|PubMed:26940431"
FT                   /id="VAR_020449"
FT   VARIANT         264
FT                   /note="D -> H"
FT                   /evidence="ECO:0000269|PubMed:9288096"
FT                   /id="VAR_010788"
FT   VARIANT         288..332
FT                   /note="Missing (in AMC5)"
FT                   /evidence="ECO:0000269|PubMed:30244176"
FT                   /id="VAR_084705"
FT   VARIANT         288
FT                   /note="R -> Q (in DYT1; increased identical protein
FT                   binding; decreased ATP-dependent chaperone mediated protein
FT                   folding; changed nuclear membrane organization;
FT                   dbSNP:rs727502811)"
FT                   /evidence="ECO:0000269|PubMed:18477710,
FT                   ECO:0000269|PubMed:24930953"
FT                   /id="VAR_070933"
FT   VARIANT         303
FT                   /note="Missing (in DYT1 and AMC5; acts as a dominant
FT                   negative; increased identical protein binding; loss of
FT                   interaction with TOR1AIP1 and TOR1AIP2 with loss of ATPase
FT                   activity induction; increased localization to the nuclear
FT                   membrane; decreased ATP-dependent chaperone mediated
FT                   protein folding; changed nuclear membrane organization;
FT                   dbSNP:rs80358233)"
FT                   /evidence="ECO:0000269|PubMed:14970196,
FT                   ECO:0000269|PubMed:15505207, ECO:0000269|PubMed:16361107,
FT                   ECO:0000269|PubMed:17428918, ECO:0000269|PubMed:18167355,
FT                   ECO:0000269|PubMed:18477710, ECO:0000269|PubMed:18827015,
FT                   ECO:0000269|PubMed:19955557, ECO:0000269|PubMed:20169475,
FT                   ECO:0000269|PubMed:21102408, ECO:0000269|PubMed:23569223,
FT                   ECO:0000269|PubMed:24930953, ECO:0000269|PubMed:27490483,
FT                   ECO:0000269|PubMed:28516161, ECO:0000269|PubMed:29053766,
FT                   ECO:0000269|PubMed:9288096"
FT                   /id="VAR_010789"
FT   VARIANT         318
FT                   /note="G -> S (in AMC5; increased localization to the
FT                   nuclear membrane; induces the formation of spheroid bodies
FT                   in cells; dbSNP:rs2030965698)"
FT                   /evidence="ECO:0000269|PubMed:29053766"
FT                   /id="VAR_084706"
FT   VARIANT         323..328
FT                   /note="Missing (found in a patient with early-onset
FT                   atypical dystonia and myoclonic features; uncertain
FT                   significance; dbSNP:rs80358235)"
FT                   /evidence="ECO:0000269|PubMed:11523564"
FT                   /id="VAR_070934"
FT   MUTAGEN         18
FT                   /note="V->F: Inhibits sequence signal cleavage."
FT                   /evidence="ECO:0000269|PubMed:17037984"
FT   MUTAGEN         20
FT                   /note="A->F: Inhibits sequence signal cleavage."
FT                   /evidence="ECO:0000269|PubMed:17037984"
FT   MUTAGEN         33
FT                   /note="V->N: N-glycosylated."
FT                   /evidence="ECO:0000269|PubMed:17037984"
FT   MUTAGEN         108
FT                   /note="K->A: Loss of ATP-binding. No effect on interaction
FT                   with KLHL14. Increases interaction with TOR1AIP1 and
FT                   TOR1AIP2. Abolishes interaction with SLC6A3."
FT                   /evidence="ECO:0000269|PubMed:15505207,
FT                   ECO:0000269|PubMed:19339278, ECO:0000269|PubMed:19535332"
FT   MUTAGEN         143
FT                   /note="N->Q: Reduces N-glycosylation."
FT                   /evidence="ECO:0000269|PubMed:10871631"
FT   MUTAGEN         158
FT                   /note="N->Q: Reduces N-glycosylation."
FT                   /evidence="ECO:0000269|PubMed:10871631"
FT   MUTAGEN         171
FT                   /note="E->Q: Loss of ATP hydrolysis. Loss of interaction
FT                   with KLHL14. Localizes in the nuclear envelope. No effect
FT                   on interaction with TOR1AIP1."
FT                   /evidence="ECO:0000269|PubMed:19339278,
FT                   ECO:0000269|PubMed:19535332, ECO:0000269|PubMed:20015956,
FT                   ECO:0000269|PubMed:23569223, ECO:0000269|PubMed:27490483"
FT   CONFLICT        259
FT                   /note="D -> H (in Ref. 3; AAP35577 and 5; AAH00674)"
FT                   /evidence="ECO:0000305"
FT   HELIX           58..68
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           73..87
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          96..102
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           108..119
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           123..125
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          129..133
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           134..137
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           141..143
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           144..161
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          166..170
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           172..174
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           177..187
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          202..207
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           211..223
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           228..230
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           233..239
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   TURN            240..245
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           247..252
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          256..262
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          264..269
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           274..287
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           294..303
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   STRAND          306..308
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   TURN            309..311
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   TURN            316..322
FT                   /evidence="ECO:0007829|PDB:5J1S"
FT   HELIX           323..328
FT                   /evidence="ECO:0007829|PDB:5J1S"
SQ   SEQUENCE   332 AA;  37809 MW;  B69B28D0B4112080 CRC64;
     MKLGRAVLGL LLLAPSVVQA VEPISLGLAL AGVLTGYIYP RLYCLFAECC GQKRSLSREA
     LQKDLDDNLF GQHLAKKIIL NAVFGFINNP KPKKPLTLSL HGWTGTGKNF VSKIIAENIY
     EGGLNSDYVH LFVATLHFPH ASNITLYKDQ LQLWIRGNVS ACARSIFIFD EMDKMHAGLI
     DAIKPFLDYY DLVDGVSYQK AMFIFLSNAG AERITDVALD FWRSGKQRED IKLKDIEHAL
     SVSVFNNKNS GFWHSSLIDR NLIDYFVPFL PLEYKHLKMC IRVEMQSRGY EIDEDIVSRV
     AEEMTFFPKE ERVFSDKGCK TVFTKLDYYY DD
//
